CRISPR-Cas9–based treatment of myocilin-associated glaucoma

Overview
Fingerprint

Fingerprint

Dive into the research topics of 'CRISPR-Cas9–based treatment of myocilin-associated glaucoma'. Together they form a unique fingerprint.

View full fingerprint

Cite this

Powered by Pure Link opens in a new tab, Scopus Link opens in a new tab & Elsevier Fingerprint Engine™ Link opens in a new tab

All content on this site: Copyright © 2026 UNT Health, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply

We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies

About web accessibility Link opens in a new tab

Report vulnerability Link opens in a new tab

Contact us